NCT06045247View on ClinicalTrials.gov

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2030

Conditions
Large B-cell Lymphoma
Interventions
DRUG

Prednisone

Given by IV (vein)

DRUG

Rituximab

Given by IV (vein)

DRUG

Cyclophosphamide

Given by IV (vein)

DRUG

Vincristine

Given by IV (vein)

DRUG

Epcoritamab

Given under the skin

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER